[The use of nifedipine for overcoming the insufficient preventive effect of lithium carbonate in patients with affective and schizoaffective psychoses]. 1997

L V Snedkova, and V K Vasiuk, and G G Fursov, and G P Panteleeva

26 patients with affective and schizoaffective psychoses either therapeutically resistant to lithium salts or with intolerance to them were treated. Control period of preventive therapy (lithium carbonate in average doses O.6-O.9 g daily) and experimental period (nifedipine, average doses 30-40 mg daily) were equal in duration, 2 years exactly. Preventive effect of nifedipine exceeded the same effect of lithium carbonate in 65.4% of patients. The total duration of affective attacks in the experimental period was reduced on 46.8% and their frequency-on 31.7% in comparison with the control period. A number of hospital admissions decreased (on 52.2%) with a simultaneous tendency to transition of a disease to a more light level (a number of attacks of cyclothymic level increased on 17.3%). The data gives ground for the perspectives of application of nifedipine in the cases of insufficient prophylactic effect or intolerance to lithium salts.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L V Snedkova, and V K Vasiuk, and G G Fursov, and G P Panteleeva
January 1991, Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952),
L V Snedkova, and V K Vasiuk, and G G Fursov, and G P Panteleeva
January 1989, Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952),
L V Snedkova, and V K Vasiuk, and G G Fursov, and G P Panteleeva
January 1998, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
L V Snedkova, and V K Vasiuk, and G G Fursov, and G P Panteleeva
January 1979, Zhurnal eksperimental'noi i klinicheskoi meditsiny,
L V Snedkova, and V K Vasiuk, and G G Fursov, and G P Panteleeva
January 1977, Neuroscience and behavioral physiology,
L V Snedkova, and V K Vasiuk, and G G Fursov, and G P Panteleeva
January 1996, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
L V Snedkova, and V K Vasiuk, and G G Fursov, and G P Panteleeva
April 1971, Ceskoslovenska psychiatrie,
L V Snedkova, and V K Vasiuk, and G G Fursov, and G P Panteleeva
January 1977, Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952),
L V Snedkova, and V K Vasiuk, and G G Fursov, and G P Panteleeva
July 1990, Der Internist,
L V Snedkova, and V K Vasiuk, and G G Fursov, and G P Panteleeva
January 1981, Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952),
Copied contents to your clipboard!